Sign in
Taking people in United StatesPhase 1

Tests dalbavancin to prevent bloodstream infections in children with high-risk leukemia

Tests dalbavancin, an antibiotic, in children and teens with leukemia receiving chemotherapy.

Key facts

Who runs it
St. Jude Children's Research Hospital
Where
Memphis, United StatesSee the site
Trial code
Registry title
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
Status
Recruiting
Phase
Phase 1
People taking part
29 people, planned
Started
22 May 2025
Expected to end
Sept 2031
Type of study
Interventional
Treatments tested
  • Dalbavancin
  • Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician)
Record updated
15 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children, teens and young adults with acute myeloid leukemia (AML) or relapsed acute lymphoblastic leukemia (ALL) who are getting chemotherapy at St. Jude. They will receive dalbavancin to help prevent bloodstream infections.

Age
25 years or younger at enrollment.
Sex
All sexes can join.
Disease stage
AML or relapsed ALL, with treatment expected to cause severe neutropenia (ANC < 500/ml) lasting more than 7 days.
Earlier treatment
Must be receiving treatment for AML or relapsed ALL at St. Jude and expected to stay in care there for at least 56 days after enrollment.

Main reasons for not taking part

  • Allergy to vancomycin, dalbavancin, teicoplanin, levofloxacin or ciprofloxacin
  • Past or current resistant bacterial infection or colonization in the prior 6 months
  • Long QT syndrome
  • Suspected or proven active bacterial infection
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Aged less than or equal to 25 years at enrollment
  • Receiving treatment for AML or relapsed ALL at St. Jude and treatment is expected to cause prolonged (> 7 days) severe neutropenia (ANC < 500/ml)
  • Expected to receive care at St. Jude for at least 56 days following enrollment on the protocol
  • Female participant, greater than or equal to 9 years old, has a documented negative pregnancy test prior to receipt of study drug

Who cannot take part

  • Documented past or current infection or colonization with pathogenic bacteria resistant to vancomycin plus either ciprofloxacin or levofloxacin, within the prior 6 months
  • Allergy to vancomycin, dalbavancin, teicoplanin, levofloxacin or ciprofloxacin (Not including non-anaphylactic vancomycin infusion reaction)
  • Any condition judged by the investigator to put the participant at high risk from participation
  • Suspected or proven active bacterial infection
  • Diagnosed with long QT syndrome
  • Alkaline phosphatase, alanine transferase or total bilirubin ≥ 3x upper limit of normal for age
  • Estimated glomerular filtration rate (EGFR) <30 mL/minute/1.73 m2
  • Inability to complete requirements of participation in the study (in the opinion of the investigator)
  • Expected survival <28 days
  • Other absolute contraindication to administration of fluoroquinolone antibiotics or dalbavancin
  • Participant is pregnant or breastfeeding a child

Where in United States

  • St. Jude Children's Research HospitalMemphis, United StatesContact: Rohith Jesudas, MBBSTaking people

About the trial

What the trial wants to find out

This is a single-arm pilot clinical trial evaluating dalbavancin-based prophylaxis in children and adolescents with acute myeloid leukemia or relapsed lymphoblastic leukemia receiving myelosuppressive chemotherapy.

Read full original descriptionShow less

Primary objective:

- To estimate the rate of bacterial bloodstream infection in pediatric patients with AML or relapsed ALL undergoing chemotherapy receiving dalbavancin-based prophylaxis

Secondary objectives:

* To describe the population pharmacokinetics of every 28 days dalbavancin up to 12 weeks in pediatric patients with AML or relapsed ALL undergoing chemotherapy * To describe the tolerability of every 28 days dalbavancin prophylaxis in pediatric patients with AML or relapsed ALL undergoing chemotherapy * To describe the acceptability of every 28 days dalbavancin prophylaxis in pediatric patients with AML or relapsed ALL undergoing chemotherapy * To estimate the rates of likely bacterial infections, Clostridioides difficile infection, and febrile neutropenia in pediatric patients receiving dalbavancin-based prophylaxis

The group in the trial

  • q28 days dalbavancin plus fluoroquinoloneTreatment being tested

    Dalbavancin given at standard treatment doses once every 28 days in combination with standard of care fluoroquinolone (ciprofloxacin or levofloxacin) prophylaxis.

    Treatment: Dalbavancin and Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Single-Arm, Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
Plain-language title
Tests dalbavancin to prevent bloodstream infections in children with high-risk leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 September 2026